Skip Navigation


JAC Advance Access originally published online on October 14, 2009
Journal of Antimicrobial Chemotherapy 2009 64(6):1341-1344; doi:10.1093/jac/dkp366
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/6/1341    most recent
dkp366v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Loutfy, M.
Right arrow Articles by Marks, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loutfy, M.
Right arrow Articles by Marks, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme

Mona Loutfy1, Esteban Ribera2, Eric Florence3, Stéphane De Wit4, Antonella Castagna5, Robert Ryan6, Andrew Hill7,*, Hilde Vanaken7, Yvonne van Delft8 and Stephan Marks8

1 Maple Leaf Medical Clinic, Toronto, Canada 2 Hopital Vall d'Hebron, Barcelona, Spain 3 Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium 4 St Pierre University Hospital, Brussels, Belgium 5 Department of Infectious Diseases/RCCS, Fondazione San Raffaele del Monte Tabor, Milan, Italy 6 Tibotec Inc., Yardley, PA, USA 7 Tibotec BVBA, Mechelen, Belgium 8 Janssen-Cilag B.V., Tilburg, The Netherlands

* Corresponding author. Tel: +44-7834-364608; Fax: +44-20-8675-1716; E-mail: microhaart@aol.com

Keywords: HIV clinical trials , fusion inhibitors , reverse transcriptase inhibitors , non-nucleoside , CD4 counts

The first 10% of the full text of this article appears below.

Sir,

The next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (formerly known as TMC125) and the fusion inhibitor enfuvirtide have both shown improved efficacy over optimized background treatments in the DUET and TORO trials, respectively.1–3 Due to the cost of enfuvirtide and the need for twice-daily injections, switching from enfuvirtide to etravirine could improve convenience and tolerability, and reduce treatment costs. Two recent pilot studies have shown sustained HIV RNA suppression, 7 months after switching from enfuvirtide to raltegravir in virologically suppressed patients.4,5 A pilot study also showed sustained HIV RNA suppression for 6 months, after switching from enfuvirtide and protease inhibitors (PIs) to . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 
Author contributions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?